GAINESVILLE, Fla., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management and collaborators will be participating in seven upcoming scientific and investor conferences.
- Discovery on Target – Boston, Mass. (September 21-24)
Stephen Potter, Chief Business Officer, will give a presentation entitled "Human Clinical Trials of AAV-Based Based Gene Therapies for Orphan Ocular Disorders" on Wednesday, September 23rd at 10:25am, EDT. The presentation will be a joint session in two of Discovery on Target's sub-conferences, Gene Therapy Breakthroughs and Targeting Ocular Disorders.
- Cell & Gene Therapy Europe – Barcelona, Spain (September 29-30)
Sue Washer, President and CEO, will be the chairperson of the morning plenary, entitled "Payer and Regulatory Evolution in Europe: Preparing the next Wave of ATMP Products for a Changing World." Ms. Washer will be introducing the plenary at 8:45am CEST on Wednesday, September 30th, and then will moderate four roundtable discussions until the session concludes at 12:30pm CET.
- Leerink Rare Disease Roundtable – New York, N.Y. (September 30)
Stephen Potter, Chief Business Officer, will be presenting at 9:15am EDT. Mr. Potter will discuss key corporate milestones in addition to providing an update on AGTC's clinical development programs.
- Stem Cell Meeting on the Mesa – La Jolla, Calif. (October 7-9)
Stephen Potter, Chief Business Officer, will be presenting a corporate overview as part of the Meeting's Partnering Forum on Wednesday, October 7th at 2:45pm PDT.
- The Retina Society 48th Annual Scientific Meeting – Paris, France (October 7-11)
Dr. Mark E. Pennesi, M.D., Ph.D., an ophthalmologist at Oregon Health & Science University specializing in retinal dystrophies and genetic disease, will report results from a study conducted in 45 participants with XLRS, titled "A Natural History Study of Subjects with X-linked Retinoschisis in Anticipation of a Phase I/II Gene Therapy Trial," on Saturday, October 10th at 11:26am CEST. The study will provide critical insight into the course and progression of XLRS, as well as methods for monitoring disease progression in clinical research settings.
- BioFlorida Annual Conference – Orlando, Fla. (October 11-13)
AGTC is proud to be sponsoring the conference's Welcome Reception on Sunday, October 11th at 5:00pm EDT. Sue Washer, President and CEO will be in attendance and will be providing brief welcoming remarks.
- ROTH Gene Therapy Corporate Access Day – New York, N.Y. (October 27)
Stephen Potter, Chief Business Officer, will be participating in the event, which will give investors the opportunity to meet with senior management of a select group of leading companies in the gene therapy sector.
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also using its gene therapy expertise to expand into disease indications with large market opportunity such as wet AMD.
Forward Looking Statements
This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs. Forward-looking statements include information concerning possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: uncertainty inherent in the regulatory review process; uncertainty regarding the ability to achieve the expected benefits from the proposed collaboration, including as a result of risks and uncertainties associated with drug development and commercialization, reliance on third parties over which AGTC may not always have full control and other risks associated with collaborations; and other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
CONTACT: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 firstname.lastname@example.org or email@example.com Corporate Contact: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 firstname.lastname@example.org
Source:Applied Genetic Technologies